NOV 12, 2021
Inherited Disease, Macular Disease, Retina/Vitreous
In this interview from AAO 2021, Dr. Mark Humayun summarizes points from his 2021 Charles L. Schepens Lecture on the background and the current state of micro- and nano-scale retinal implants intended to restore and preserve sight. Most implants under development are geared toward end-stage retinitis pigmentosa or macular degeneration, including retinal pigment epithelium (RPE) transplantation for geographic atrophy. As these implants mature, Dr. Humayun envisions better resolution, improved field of view and performance in low light, and applications that extend to patients with other degenerative retinal diseases.
Relevant financial disclosures: Dr. Humayun receives consulting fees from or is an equity owner of Golden Eye, Intellimicro, Regenerative Patch Technologies, and Second Sight Medical Products.